Wall Street Zen Downgrades Henry Schein (NASDAQ:HSIC) to Hold

Key Points

• Henry Schein has been downgraded by Wall Street Zen from a "buy" rating to a "hold" rating, alongside similar downgrades from Baird R W.
• The company's recent quarterly earnings revealed an EPS of $1.10, missing analysts' estimates, while revenue was slightly above expectations at $3.24 billion.
• Henry Schein has a consensus rating of "Hold" with an average target price of $76.67, indicating cautious sentiment among analysts.

Wall Street Zen lowered shares of Henry Schein (NASDAQ:HSIC - Free Report) from a buy rating to a hold rating in a research note released on Sunday.

Other equities analysts have also issued research reports about the company. Baird R W lowered Henry Schein from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 14th. Robert W. Baird reissued a "neutral" rating and set a $72.00 target price (down previously from $82.00) on shares of Henry Schein in a report on Monday, July 14th. Stifel Nicolaus reissued a "hold" rating and set a $75.00 target price (down previously from $80.00) on shares of Henry Schein in a report on Friday, July 25th. JPMorgan Chase & Co. reduced their target price on Henry Schein from $80.00 to $76.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Finally, Evercore ISI raised Henry Schein from an "in-line" rating to an "outperform" rating and set a $83.00 target price for the company in a report on Tuesday, August 26th. Five equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $76.67.

Henry Schein Price Performance

Shares of Henry Schein stock traded down $0.54 on Friday, hitting $69.01. The company's stock had a trading volume of 1,115,039 shares, compared to its average volume of 1,429,852. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41. Henry Schein has a 1 year low of $60.56 and a 1 year high of $82.49. The firm has a fifty day moving average price of $69.32 and a 200-day moving average price of $69.48. The company has a market capitalization of $8.37 billion, a price-to-earnings ratio of 22.26, a price-to-earnings-growth ratio of 2.29 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.24 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. Henry Schein's revenue for the quarter was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. As a group, sell-side analysts anticipate that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

Large investors have recently made changes to their positions in the stock. CYBER HORNET ETFs LLC purchased a new stake in shares of Henry Schein in the second quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the second quarter valued at approximately $27,000. Investment Management Corp VA ADV acquired a new position in Henry Schein in the fourth quarter valued at approximately $32,000. Rakuten Securities Inc. acquired a new position in Henry Schein in the first quarter valued at approximately $34,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in Henry Schein in the second quarter valued at approximately $43,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.